Role of antiepileptic drugs in the management of eating disorders

CNS Drugs

Volumn 23, Issue 2, 2009, Pages 139-156

  McElroy, Susan L ^a,b   Guerdjikova, Anna I ^a,b   Martens, Brian ^a,b   Keck Jr , Paul E ^a,b   Pope, Harrison G ^c,d   Hudson, James I ^c,d  

^a LINDNER CENTER OF HOPE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MCLEAN HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FELBAMATE; FLUOXETINE; GABAPENTIN; LITHIUM; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; ONDANSETRON; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRAMIPEXOLE; PREGABALIN; SIBUTRAMINE; TIAGABINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AMENORRHEA; ANOREXIA; ANOREXIA NERVOSA; ATTENTION DISTURBANCE; BINGE EATING DISORDER; BULIMIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONCENTRATION LOSS; CONFUSION; COPROPHAGY; CYCLOTHYMIA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; EATING DISORDER; EEG ABNORMALITY; FATIGUE; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HUMAN; LIVER FAILURE; MEMORY DISORDER; MOOD DISORDER; NAUSEA; NERVOUSNESS; NIGHT EATING SYNDROME; OBESITY; PARESTHESIA; PICA; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SLEEP RELATED EATING DISORDER; SOMNOLENCE; TASTE DISORDER; TASTE PERVERSION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; EATING DISORDERS; HUMANS;

EID: 59149087853     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923020-00004     Document Type: Review

References (169)

1. Hudson JI, Hiripi E, Pope Jr HG, et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2006; 61: 348-58
2. Yager J, Powers PS, editors. Clinical manual of eating disorders. Washington (DC): American Psychiatric Publishing, 2007
3. Winkelman JW. Sleep-related eating disorder and night eating syndrome: sleep disorders, eating disorders, or both? Sleep 2006; 29: 876-7
4. MacClancy J, Macbeth H, Henry J, et al. Consuming the inedible: cross-disciplinary approaches. Oxford: Berghahn, 2007
5. American Psychiatric Association. Treatment of patients with eating disorders. 3rd ed. Am J Psychiatry 2006; 163 Suppl. 7: 4-54
6. Berkman ND, Bulik CM, Brownley KA, et al. Management of eating disorders. Evid Rep Technol Assess (Full Rep) 2006; 135: 1-166
7. Kaplan AS. Anticonvulsant treatment of eating disorders. In: Garfinkel PE, Garner DM, editors. The role of drug treatments for eating disorders. New York: Brunner/ Mazel, 1987: 96-123
8. Hudson JI, Pope Jr HG. The role of anticonvulsants in the treatment of bulimia. In: McElroy SL, Pope Jr HG, editors. Use of anticonvulsants in psychiatry. New York: Oxford University Press, 1988: 141-53
9. McElroy SL, Guerdjikova A, Keck Jr PE, et al. Antiepileptic drugs in obesity, psychotropic-induced weight gain, and eating disorders. In: McElroy SL, Keck Jr PE, Post RM, editors. Antiepileptic drugs to treat psychiatric disorders. New York: Informa Healthcare, 2008; 283-309
10. Bulik CM, Sullivan PF, Kendler KS. An empirical study of the classification of eating disorders. Am J Psychiatry 2000; 157: 886-95
11. Wilfley DE, Bishop ME, Wilson GT, et al. Classification of eating disorders: toward DSM-V. Int J Eat Disord 2007; 40 Suppl.: S123-9
12. World Health Organization. International statistical classification of diseases. 10th ed. Geneva: World Health Organization, 2007
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994
14. Machado PP, Machado BC, Goncalves S, et al. The prevalence of eating disorders not otherwise specified. Int J Eat Disord 2007; 40: 212-7
15. Rockert W, Kaplan AS, Olmsted MP. Eating disorder not otherwise specified: the view from a tertiary care treatment center. Int J Eat Disord 2007; 40 Suppl.: S99-103
16. Papadioiykis V, Mimidis K. The rumination syndrome in adults: a review of the pathophysiology, diagnosis and treatment. J Postgrad Med 2007; 53: 203-6
17. O'Reardon JP, Peshek A, Allison KC. Night eating syndrome: diagnosis, epidemiology and management. CNS Drugs 2005; 19: 997-1008
18. Streigel-Moore RH, Franko DL, May A, et al. Should night eating syndrome be included in the DSM? Int J Eat Disord 2006; 39: 544-9
19. American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual, 2nd ed. Westchester (IL): American Academy of Sleep Medicine, 2005
20. Winkelman JW. Clinical and polysomnographic features of sleep-related eating disorder. J Clin Psychiatry 1998; 59: 14-9
21. Plante DT, Winkelman JW. Parasomnias. Psychiatr Clin North Am. 2006; 29: 969-87
22. Uher R, Treasure J. Brain lesions and eating disorders. J Neurol Neurosurg Psychiatry 2005; 76: 852-7
23. Theisen FM, Linden A, König IR, et al. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003; 110: 111-21
24. Stunkard AJ. Eating patterns and obesity. Psychiatr Q 1959; 33: 284-95
25. Volkow ND, O'Brien CP. Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry 2007; 164: 708-10
26. Devlin MJ. Is there a place for obesity in DSM-V? Int J Eat Disord 2007; 40 Suppl.: S83-8
27. Gilmour J, Skuse D, Pembrey M. Hyperphagic short stature and Prader-Willi syndrome: a comparison of behavioral phenotypes, genotypes and indices of stress. Br J Psychiatry 2001; 179: 250-4
28. Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 2005; 128: 2763-76
29. Daousi C, Dunn AJ, Foy PM, et al. Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 2005; 118: 45-50
30. Rose EA, Porcerelli JH, Neale AV. Pica: common but commonly missed. J Am Board Fam Pract 2000; 13: 353-8
31. Rand CS, Macgregor AM, Stunkard AJ. The night eating syndrome in the general population and among postoperative obesity surgery patients. Int J Eat Disord 1997; 22: 65-9
32. Winkelman JW, Herzog DB, Fava M. The prevalence of sleep-related eating disorder in psychiatric and nonpsychiatric populations. Psychol Med 1999; 29: 1461-6
33. Hay P. Quality of life and bulimic eating disorder behaviors: findings from a community based sample. Int J Eat Disord 2003; 33: 434-42
34. Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Comp Psychiatry 2007; 48: 124-31
35. Hudson JI, Lalonde JK, Berry JM, et al. Binge eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry 2006; 63: 313-9
36. Slof-Op't Landt MC, van Furth EF, Meulenbelt I, et al. Eating disorders: from twin studies to candidate genes and beyond. Twin Res Hum Genet 2005; 8: 467-82
37. Javaris KN, Laird NM, Reichborn-Kjennerud T, et al. Familiality and heritability of binge eating disorder: results of a case-control family study and a twin study. Int J Eating Disord 2008; 41: 174-9
38. Cnattingius S, Hultman CM, Dahl M, et al. Very preterm birth, birth trauma, and the risk of anorexia nervosa among girls. Arch Gen Psychiatry 1999; 56: 634-8
39. Favaro A, Tenconi E, Santonastaso P. Perinatal factors and the risk of developing anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry 2006; 63: 82-8
40. National Institute for Clinical Excellence (NICE). Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline no 9. London: National Institute for Clinical Excellence, 2004 Jan
41. Mond JM, Jay PJ, Rodgers B, et al. Health service utilization for eating disorders: findings from a community-based study. Int J Eat Disord 2007; 40: 399-408
42. Hudson JI, Pope Jr HG, Carter WP. Pharmacologic therapy of bulimia nervosa. In: Goldstein E, editor. The management of eating disorders and obesity. Totowa (NJ): Humana Press, 1999: 19-32
43. Carter WP, Hudson JI, Lalonde JK, et al. Pharmacologic treatment of binge eating disorder. Int J Eat Disord 2003; 34 Suppl.: 74-88S
44. Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets 2004; 5: 301-7
45. Steffen KJ, Roerig JL, Mitchell JE, et al. Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs 2006; 11: 315-36
46. Shapiro JR, Berkman ND, Brownley KA, et al. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 321-36
47. Brownley KA, Berkman ND, Sedway JA, et al. Binge eating disorder treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 337-48
48. McElroy SL, Guerdjikova AI, O'Melia A, et al. Pharmacotherapy of the eating disorders. In: Agras WS, editor. Oxford handbook of eating disorders. New York: Oxford University Press. In press
49. O'Reardon JP, Allison KC, Martino NS, et al. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry 2006; 163: 893-8
50. Horne RL, Ferguson JM, Pope Jr HG, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49: 262-6
51. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial [published errata appear in JAMA 2006; 296: 934 and JAMA 2007; 298: 2008]. JAMA 2006; 295: 2605-12
52. Bulik CM, Berkman ND, Brownley KA, et al. Anorexia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40: 310-20
53. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60: 1109-16
54. Milano W, Petrella C, Casella A, et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenalin, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005; 22: 25-31
55. Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008; 165: 51-8
56. Faris PL, Kim SW, Meller WH, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomized, double-blind trial. Lancet 2000; 355: 792-7
57. McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 2007; 68: 390-8
58. Provini F, Albani F, Vetrugno R, et al. A pilot double-blind placebo-controlled trial of low-dose pramipexole in sleep-related eating disorder. Eur J Neurol 2005; 12: 432-6
59. Bissada H, Tasca GA, Barber AM, et al. Olanzapine in the treatment of low body weight and obsessional thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165: 1281-8
60. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-64
61. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004; 10: 685-92
62. Johannessen Landmark C. Antiepileptic drugs in nonepilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27-47
63. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85-110
64. McElroy SL, Keck Jr PE, Post RM, editors. Antiepileptic drugs to treat psychiatric disorders. New York: Informa Healthcare, 2008
65. McElroy SL, Kotwal R, Keck Jr PE, et al. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord 2005; 86: 107-27
66. Brewerton TD, George MS. Is migraine related to the eating disorders? Int J Eat Disord 1993; 14: 75-9
67. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27: 263-72
68. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361: 1677-85
69. Johnson BA, Rosenthal N, Capece J, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298: 1641-51
70. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75: 233-40
71. Polycarpon A, Papanikolaou P, Ioannidis JP, et al. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2005; (3): CD005064
72. Zanarini M. Antiepileptic drugs in personality disorders. In: McElroy SL, Keck Jr PE, Post RM, editors. Antiepileptic drugs to treat psychiatric disorders. New York: Informa Healthcare, 2008: 343-8
73. Biton V. Effect of antiepileptic drugs on body weight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17: 781-91
74. Gao O, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett 2008; 582: 132-41
75. Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92: 263-71
76. Clifton PG, Kennett GA. Monoamine receptors in the regulation of feeding behaviour and energy balance. CNS Neurol Disord Drug Targets 2006; 5: 293-312
77. Uevama E, Morikawa Y, Yasuda T, et al. Attenuation of fasting-induced phosphorylation of mitogen-activated protein kinases (ERK/p38) in the mouse hypothalamus in response to refeeding. Neurosci Lett 2004; 371: 40-4
78. Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124: 1277-85
79. Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA trasporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003; 116: 1-6
80. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007; 64: 2090-103
81. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007; 30: 230-40
82. Brill J, Lee M, Zhao S, et al. Chronic valproic acid treatment triggers increased neuropeptide y expression and signaling in rat nucleus reticularis thalami. J Neurosci 2006; 26: 6813-22
83. Husum H, Van Kammen D, Termeer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line 'depressed' rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacol 2003; 28: 1292-9
84. Kwak SE, Kim JE, Kim DS, et al. Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil. Neuropeptides 2005; 39: 507-13
85. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial [published erratum appears in Am J Psychiatry 2003; 160: 612]. Am J Psychiatry 2003; 160: 255-61
86. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61: 1039-48
87. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1897-906
88. Herridge PL, Pope Jr HG. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985; 5: 229-30
89. McElroy SL, Keck Jr PE, Pope Jr HG. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16-24
90. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69: 273-94
91. Greenway FL, Dahms WT, Bray GA. Phenytoin as a treatment of obesity associated with compulsive eating. Curr Ther Res 1977; 21: 338-42
92. Wermuth BM, Davis KL, Hollister LE, et al. Phenytoin treatment of binge eating syndrome. Am J Psychiatry 1977; 134: 1249-53
93. Green RS, Rau JH. Treatment of compulsive eating disturbances with anticonvulsant medication. Am J Psychiatry 1974; 131: 428-32
94. Rau JH, Green RS. Compulsive eating: a neuropsychologic approach to certain eating disorders. Compr Psychiatry 1975; 16: 223-31
95. Weiss T, Levitz L. Diphenylhydantoin treatment of bulimia [letter]. Am J Psychiatry 1976; 133: 1093
96. Rau JH, Green RS. Soft neurological correlates of compulsive eaters. J Nerv Ment Dis 1978; 166: 435-7
97. Moore SL, Rakes SM. Binge eating: therapeutic response to diphenylhydantoin [case report]. J Clin Psychiatry 1982; 43: 385-6
98. Parsons JM, Sapse AT. Significance of hypercortisolism in anorexia nervosa. J Orthomolecular Psychiatry 1985; 14: 13-8
99. Szyper MS, Mann JD. Anorexia nervosa as an interictal symptom of partial complex seizures [abstract]. Neurology 1978; 28: 335
100. Kaplan AS, Garfinkel PE, Darby PL, et al. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983; 140: 1225-6
101. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
102. Hudson JI, Pope Jr HG, Jonas JM, et al. Treatment of anorexia nervosa with antidepressants. J Clin Psychopharmacol 1985; 5: 17-23
103. Young CR, Mazure CM. Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine [letter]. J Clin Psychiatry 1998; 59: 622
104. Stewart JT. Treatment of coprophagia with carbamazepine [letter]. Am J Psychiatry 1995; 152: 295
105. Jawed SH, Krishnan VH, Prasher VP, et al. Worsening of pica as a symptom of depressive illness in a person with severe mental handicap. Br J Psychiatry 1993; 162: 835-7
106. Tachibana N, Sugita Y, Teshima Y, et al. A case of anorexia nervosa associated with epileptic seizures showing favorable responses to sodium valproate and clonazepam. Jpn J Psychiatry Neurol 1989; 43: 77-84
107. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61: 368-72
108. Schenck CH, Hurwitz TD, O'Connor KA, et al. Additional categories of sleep-related eating disorders and the current status of treatment. Sleep 1993; 16: 457-66
109. Yeh SB, Schenck CH. Sleep-related eating disorder in a 29 year-old man: a case report with diagnostic polysomnographic findings. Acta Neurol Taiwan 2007; 16: 106-10
110. McElroy SL, Keck Jr PE. Topiramate. In: Schatzberg AF, Nemeroff CB, editors. The American Psychiatric Press textbook of psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Press. In press
111. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo controlled study. Biol Psychiatry 2005; 57: 495-9
112. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind placebo-controlled study. J Clin Psychiatry 2004; 65: 1515-9
113. Nickel C, Lahman C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized double-blind, placebo-controlled study. J Affect Disord 2005; 87: 243-52
114. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335-41
115. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003; 64: 1449-54
116. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005; 38: 295-300
117. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007; 68: 1324-32
118. Garner DM, Olmsted MP. Scoring the eating disorder inventory. Am J Psychiatry 1986; 143: 680-1
119. Garner DM, Garfinkel PE. The Eating Attitudes Test: an index of the symptoms of anorexia nervosa. Psychol Med 1979; 9: 273-9
120. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5
121. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare (ADM), 1976: 76-338
122. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
123. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-11
124. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity [published erratum appears in J Clin Psychiatry 2005; 66: 138]. J Clin Psychiatry 2004; 65: 1463-9
125. Barrat E, Stanford M. Impulsiveness: impulsiveness in personality characteristics of the personality disordered client. New York (NY): Wiley, 1995
126. Stunkard A, Messick S. Eating inventory manual. San Antonio (TX): The Psychological Corporation, Harcourt Brace & Company, 1988
127. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11 Suppl 3: 89-95
128. Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among obese persons. Addict Behav 1982; 7: 47-55
129. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71
130. Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder. Am J Psychiatry 2001; 158: 967-8
131. Appolinario JC, Fontenelle LF, Papelbaum M, et al. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002; 47: 271-3
132. Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment-resistant depression and binge eating disorder. Bipolar Disord 2002; 4: 271-3
133. Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorders. Am J Psychiatry 2002; 159: 1246-7
134. Barbee JG. Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int J Eat Disord 2003; 33: 456-72
135. De Bernardi C, Ferraris S, D'Innella P, et al. Topiramate for binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 339-41
136. Zilberstein B, Pajecki D, Garcia de Brito AC, et al. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg 2004; 14: 802-5
137. Guerdjikova AI, Kotwal R, McElroy SL. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg 2005; 15: 273-7
138. Knable M. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry 2001; 158: 322-3
139. Dolberg OT, Barkai G, Gross Y, et al. Differential effects of topiramate in patients with traumatic brain injury and obesity: a case series. Psychopharmacol (Berl) 2005; 179: 838-45
140. Winkelman JW. Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med 2003; 4: 243-6
141. Tucker P, Masters B, Nawar O. Topiramate in the treatment of comorbid night eating syndrome and PTSD: a case study. Eat Disord 2004; 12: 75-8
142. Winkelman JW. Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series. J Clin Psychiatry 2006; 67: 1729-34
143. Martinez-Salio A, Soler-Algarra S, Calvo-Garcia I, et al. Nocturnal sleep-related eating disorder that responds to topiramate [in Spanish]. Rev Neurol 2007; 45: 276-9
144. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1035-9
145. Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. Am J Psychiatry 2002; 159: 2112-3
146. Colom F, Vieta E, Benabarre H, et al. Topiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001; 62: 475-6
147. Chung AM, Reed MD. Intentional topiramate ingestion in an adolescent female. Ann Pharmacother 2004; 38: 1439-42
148. Gadde KM, Franciscy DM, Wagner II HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289: 1820-5
149. McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004; 65: 50-6
150. Cordas TA, Tavares H, Calderoni DM, et al. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9: 769-71
151. Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: weight loss associated with levetiracetam. BMJ 2003; 327: 905
152. Gelisse P, Juntas-Morales R, Genton P, et al. Dramatic weight loss with levetiracetam. Epilepsia 2008; 49: 308-15
153. Meredith CH. A single-center, double-blind, placebo-controlled evaluation of lamotrigine of obesity in adults. J Clin Psychiatry 2006; 67: 258-62
154. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287-91
155. York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of Osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000; 16: 967-75
156. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000; 8: 656-63
157. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961-6
158. Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002; 26: 344-53
159. Lalonde J, Samson P, Poulin S, et al. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol Behav 2004; 80: 415-20
160. Batterham RL, Ffytche DH, Rosenthal JM, et al. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007; 450: 106-9
161. Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol 2007; 15: 481-91
162. Schiffer WK, Gerasimov MR, Marsteller DA, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 2001; 42: 196-8
163. Nasser JA, Gluck ME, Geliebter A. Impulsivity and test meal intake in obese binge eating women. Appetite 2004; 43: 303-7
164. McElroy S, Kotwal R. Binge eating. In: Hollander E, Stein DJ, editors. Clinical manual of impulse-control disorders. Washington, DC: American Psychiatric Publishing, 2006: 115-48
165. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, et al. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp 30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 2005; 289: E1015-22
166. Liang Y, Chen X, Osborne M, et al. Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 2005; 7: 360-9
167. Wilkes JJ, Nelson E, Osborne M, et al. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005; 288: E617-24
168. Ha E, Yim SV, Jung KH, et al. Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. Pharmacogenomics J 2006; 6: 327-32
169. De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007; 7: 879-84